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Heparins are the standard anticoagulants in clinical med-icine. However, in 1% to 3% of all patients this med-ication is complicated by heparin-inducedthrombocytopenia type II (HIT II). This immunologic
reaction causes platelet activation and is often associated with
thromboses or embolism. Patients with HIT II should not be
exposed to heparins. This poses a problem, particularly in cardiac
surgery involving cardiopulmonary bypass (CPB), because no safe
alternatives to heparin are available. The prolonged biologic elim-
ination and unavailability of an antidote for current alternative
anticoagulants, such as danaparoid or r-hirudin, may result in a
persistent anticoagulant effect and severe hemorrhage. 
Poetzsch, Klovekorn, and Madlener1 recently proposed that
surgery be delayed until the HIT II antibodies become unde-
tectable in laboratory assays and that unfractionated heparins then
be used for anticoagulation during CPB. In those patients, after the
short period of “contamination” with unfractionated heparins dur-
ing CPB, HIT II antibodies remained untraceable. However, this
study involved only 10 patients and lacks detail with regard to the
duration of CPB. Additionally, in patients with cardiovascular dis-
ease, the operation often cannot be delayed until the antibodies are
cleared, a period of approximately 40 days.2 Therefore, this strat-
egy is applicable only for selected patients. 
We3 recently introduced a new concept in which unfractionated
heparins are used after platelet paralysis with the short-acting com-
petitive platelet glycoprotein IIb/IIIa (GP IIb/IIIa) antagonist
tirofiban for inhibition of HIT II–associated thromboembolism. No
thromboses, thromboembolic complications, or postoperative hemor-
rhage were observed. However, this study involved only 10 patients.
Here we report on our 1-year experience with the use of this strategy. 
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Patients and Methods 
This protocol was used in 47 patients with HIT II undergoing car-
diovascular surgery. In 4 patients, surgery was necessary because
of acute HIT II–induced thromboembolism (pulmonary artery
embolism = 2, caval-atrial thrombus = 1, mitral valve prosthesis
thrombosis = 1). In 33 patients urgent surgery was necessary
because of beginning cardiac decompensation. The remaining 10
patients underwent elective surgery. This included complex opera-
tions such as reoperations, combined procedures, transplantations,
and major aortic surgery.
Tirofiban (Aggrastat; Merck & Co, Inc, Frankfurt, Germany)
was administered 10 minutes before the administration of unfrac-
tionated heparins (400 IU/kg). The dosage of tirofiban followed
the RESTORE protocol with a bolus of 10 µg · kg–1 and a contin-
uous infusion of 0.15 µg · kg–1 · min–1. The infusion was stopped
1 hour before the conclusion of CPB. Immediately after surgery,
thrombosis prophylaxis with r-hirudin (Refludan; Aventis Pharma,
Frankfurt, Germany) to a target activated partial thromboplastin
time of 40 to 60 seconds was initiated. 
Results 
In 35 of the 47 patients, the actual presence of HIT II antibodies
was detected in the heparin-induced platelet aggregation assay. In
the remaining 12 patients, HIT II was diagnosed previously and the
antibody status was not further evaluated. 
No thromboses or embolic complications were observed either
during heparinization or during the postoperative treatment.
Transfusion of platelet concentrates was necessary in only 3
patients with severe preoperative thrombocytopenia (<40,000/µL).
Transfusion requirements ranged from 0 to 8 units of packed red
blood cells (mean 2 ± 2.6 units) and 0 to 9 units of fresh frozen
plasma (mean 3.3 ± 2.2 units). The 24-hour postoperative blood
loss ranged from 150 to 900 mL with a mean of 410 ± 180 mL. In
all patients, transfusion requirements and postoperative blood loss
were comparable with our institutional standards in patients with
analogous preoperative clinical conditions and operations. No
patient needed reexploration because of postoperative hemorrhage.
Two patients died because of multiorgan failure as a result of
myocardial failure. One patient needed prolonged care in the inten-
sive care unit because of respiratory failure. All other patients were
discharged from the hospital on schedule.
Comment
The effectiveness of platelet inhibition with GP IIb/IIIa antagonists
for the treatment of acute coronary syndromes has been validated
in large clinical trials. In vitro studies proved these agents to be
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able to inhibit HIT II–induced platelet aggregation.4 Combining
these drugs with r-hirudin improved the outcome of patients hav-
ing an acute HIT II reaction as compared with therapy with
r-hirudin alone.5 These clinical data provide further convincing
evidence that GP IIb/IIIa antagonists in vivo inhibit a central path-
way of the HIT II cascade. 
Our data clearly demonstrate that inhibition of the GP IIb/IIIa
receptor during heparinization for CPB, with HIT antibodies pres-
ent, effectively prevents HIT II–associated complications. The
pharmacokinetic profile of an immediate and short-acting GP
IIb/IIIa antagonist enables fast institution of CPB, close control of
platelet aggregation, and reinstitution of hemostasis. Despite an
overlap with r-hirudin during the period of recovery of platelet
function, no bleeding complications were observed. 
The protocol has been validated in a large number of patients. It
represents a safe and practicable option for the treatment of these
high-risk patients, even in cases of emergency and complex surgery.
We are indebted to Ms Anne Gale for her editorial assistance.
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